Type Whole antibody Target KIR2DL1/2/3 CAS Number 1000676-41-4 | Source Human ATC code none ChemSpider none | |
Lirilumab (INN) is a human monoclonal antibody designed for the treatment of cancer. It binds to KIR2DL1/2L3.
This drug was developed by Innate Pharma and is licensed to Bristol-Myers Squibb.
Clinical trials
A phase 2 clinical trial for acute myeloid leukemia (AML) was terminated early ("failed") in 2017.
References
Lirilumab Wikipedia(Text) CC BY-SA